Scarica l'app Stockscreener
35.34
11.70%
3.72
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TEVA Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$31.62
Aprire:
$34
Volume 24 ore:
13.06M
Relative Volume:
1.70
Capitalizzazione di mercato:
$41.17B
Reddito:
$17.41B
Utile/perdita netta:
$1.43B
Rapporto P/E:
29.01
EPS:
1.2182
Flusso di cassa netto:
$1.00B
1 W Prestazione:
+13.13%
1M Prestazione:
+22.89%
6M Prestazione:
+74.59%
1 anno Prestazione:
+126.70%
Intervallo 1D:
$33.92
$35.62
Intervallo di 1 settimana:
$30.02
$35.62
Portata 52W:
$14.99
$37.34
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile
Nome
Teva Pharmaceutical Industries Ltd Adr
Settore
Telefono
972 (3) 914-8213
Indirizzo
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
Compare TEVA vs TAK, ZTS, HLN, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.36 | 36.82B | 17.41B | 1.43B | 1.00B | 1.2182 |
TAK
Takeda Pharmaceutical Co Adr
|
16.36 | 51.84B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
114.18 | 49.05B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.295 | 42.09B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
571.29 | 24.94B | 3.18B | 1.33B | 1.04B | 27.90 |
Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-12-05 | Iniziato | Scotiabank | Sector Outperform |
| 2025-06-06 | Iniziato | Goldman | Buy |
| 2025-05-28 | Iniziato | Truist | Buy |
| 2025-05-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-07-10 | Aggiornamento | Argus | Hold → Buy |
| 2024-03-08 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2024-02-12 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-11-27 | Aggiornamento | UBS | Neutral → Buy |
| 2023-07-06 | Aggiornamento | UBS | Sell → Neutral |
| 2023-05-25 | Iniziato | Morgan Stanley | Equal-Weight |
| 2023-05-18 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-01-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-11-14 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-04 | Downgrade | UBS | Neutral → Sell |
| 2022-10-21 | Ripresa | Jefferies | Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-06-14 | Ripresa | UBS | Neutral |
| 2022-05-17 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-05-04 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-03-25 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | Downgrade | Argus | Buy → Hold |
| 2021-10-28 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | Downgrade | UBS | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | Iniziato | Oppenheimer | Perform |
| 2020-08-06 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-07-27 | Ripresa | Goldman | Neutral |
| 2020-06-01 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-04-24 | Ripresa | Citigroup | Neutral |
| 2020-04-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-02-24 | Downgrade | Edward Jones | Hold → Sell |
| 2019-11-12 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-10-17 | Aggiornamento | Gabelli & Co | Hold → Buy |
| 2019-08-07 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-07-19 | Iniziato | Wolfe Research | Peer Perform |
| 2019-07-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | Ripresa | Credit Suisse | Neutral |
| 2019-07-05 | Aggiornamento | Argus | Hold → Buy |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-06-03 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-05-30 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | Downgrade | UBS | Buy → Neutral |
| 2019-03-20 | Iniziato | SunTrust | Hold |
| 2019-03-07 | Ripresa | UBS | Buy |
Mostra tutto
Teva Pharmaceutical Industries Ltd Adr Borsa (TEVA) Ultime notizie
Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva's Pivot to Growth Strategy - Benzinga
Intel Upgraded, Toyota Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Dermatomycoses Market Report 2025-2035, Profiles of Prominent Players - GlobeNewswire Inc.
Is It Too Late To Reassess Teva (TEVA) After Its 118.5% One-Year Surge? - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After The Home Ground Schizophrenia Platform Launch - Sahm
Teva- Pharmaceutical Industries Ltd.ADR (TEVA) News, Articles, Events & Latest Updates - Stocktwits
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners - Sahm
Teva Pharmaceutical (ADR) stock (US88162G1031): Why generic drug execution is suddenly worth a close - AD HOC NEWS
Does Biosimilar Wins in Osteoporosis and Allergy Care Change The Bull Case For Teva (TEVA)? - Sahm
A Look At Teva Pharmaceutical Industries (TEVA) Valuation After Recent Biosimilar Regulatory Milestones - Sahm
Target Upgraded, Robinhood Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
How Investors Are Reacting To Teva (TEVA) Advancing Its Biosimilar Pipeline With New FDA and EMA Milestones - Sahm
Assessing Teva Pharmaceutical Industries (TEVA) Valuation After New Biosimilar Approvals And Pipeline Progress - Sahm
Missile Strike Tests Teva Supply Resilience And Biosimilar Growth Plans - Sahm
Price to sales ratio of Teva Pharmaceutical Industries Limited Sponsored ADR – BSESOF:TEV - TradingView
Teva’s New Biosimilars Test Growth Plan And Earnings Reshaping Potential - Sahm
ETFs Investing in Teva Pharmaceutical Industries Limited Sponsored ADR Stocks - TradingView
How Investors May Respond To Teva (TEVA) Advancing TEV ‘325 In Biologics For Inflammatory Diseases - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Recent Share Price Weakness - Sahm
TEVA Stock Price, Quote & Chart | TEVA PHARMACEUTICAL-SP ADR (NYSE:TEVA) - ChartMill
Teva Pharmaceutical Industries Limited Sponsored ADR Trade Ideas — LS:883035 - TradingView
Teva Releases Q1 2026 Aide Memoire - Sahm
Will Teva’s (TEVA) Olanzapine LAI Milestone and Legal Win Change Its Innovation-Led Narrative? - Sahm
Tesla Upgraded, Super Micro Computer Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
How Teva’s Blackstone-Backed ‘Pivot to Growth’ Strategy Could Reshape Teva Pharmaceutical Industries (TEVA) Investors - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Pivot To Growth Update At Leerink Conference - Sahm
Teva Blackstone Duvakitug Deal Tests Growth Story And Concentration Risk - Sahm
Teva Drug Updates Support Branded Growth Story And Valuation Upside Potential - Sahm
What's Driving the Market Sentiment Around Teva Pharmaceutical Industries Ltd? - Sahm
Duvakitug IBD Data and TEV-749 Filing Might Change The Case For Investing In Teva (TEVA) - Sahm
Teva to Present at the Upcoming Investor Conferences in March - Sahm
J&J Stock Up 38% in 6 Months: Should You Buy, Sell or Hold? - Finviz
Where is Teva Pharmaceutical Industries Limited (TEVA) Headed? - Finviz
Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz
FDA Accepts Teva's New Long-Acting Schizophrenia Treatment Application - Sahm
Assessing Teva Pharmaceutical Industries (NYSE:TEVA) Valuation After Its Strong Recent Share Price Momentum - Sahm
Truist Boosts Teva (TEVA) Stock Target Amid Pipeline Growth Opportunities - Finviz
Corcept Therapeutics Stock Plunges As Court Clears Teva Generic - Sahm
Goldman Sachs See Teva Pharmaceutical Industries Limited (TEVA) Driving Double-Digit Earnings Growth Through 2026 - Finviz
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price, Trades & News - GuruFocus
Teva’s Duvakitug Data Puts Ulcerative Colitis And Crohn’s Bet In Focus - Sahm
Should You Invest in Teva Pharmaceutical (TEVA), Here's What the Street Has to Say - Finviz
Teva Pharmaceutical Industries Ltd Adr Azioni (TEVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.74%
0.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):